WO2014155278A3 - Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 - Google Patents

Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 Download PDF

Info

Publication number
WO2014155278A3
WO2014155278A3 PCT/IB2014/060110 IB2014060110W WO2014155278A3 WO 2014155278 A3 WO2014155278 A3 WO 2014155278A3 IB 2014060110 W IB2014060110 W IB 2014060110W WO 2014155278 A3 WO2014155278 A3 WO 2014155278A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
patient
antagonist
treating
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/060110
Other languages
English (en)
Other versions
WO2014155278A2 (fr
Inventor
Arndt Holger BRACHAT
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2014155278A2 publication Critical patent/WO2014155278A2/fr
Publication of WO2014155278A3 publication Critical patent/WO2014155278A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouvelles méthodes prédictives et thérapies personnalisées destinées au traitement d'une maladie auto-immune (AI) choisie parmi le psoriasis, l'uvéite, la polyarthrite rhumatoïde (PR), le rhumatisme psoriasique (RP), la spondylarthrite ankylosante (SA) et la sclérose en plaques (SEP) Plus particulièrement, l'invention concerne des méthodes de traitement d'un patient atteint d'une maladie AI par administration sélective d'un antagoniste de l'IL-17, par exemple, d'un anticorps anti-IL-17, tel que le sécukinumab, audit patient sur la base du fait que ce patient présente une prédisposition génétique à développer une réponse favorable au traitement par l'antagoniste de l'IL-17. L'invention concerne en outre des sources d'information sous forme transmissible, des méthodes diagnostiques et des trousses servant à prédire la probabilité qu'un patient atteint d'uvéite, de PR, RP, SA, psoriasis ou SEP développe une réponse au traitement par un antagoniste de l'IL-17, par exemple, un anticorps anti-IL-17, tel que le sécukinumab.
PCT/IB2014/060110 2013-03-26 2014-03-24 Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17 Ceased WO2014155278A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361805257P 2013-03-26 2013-03-26
US61/805,257 2013-03-26

Publications (2)

Publication Number Publication Date
WO2014155278A2 WO2014155278A2 (fr) 2014-10-02
WO2014155278A3 true WO2014155278A3 (fr) 2014-12-18

Family

ID=50513390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060110 Ceased WO2014155278A2 (fr) 2013-03-26 2014-03-24 Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17

Country Status (1)

Country Link
WO (1) WO2014155278A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356279B (es) 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
WO2017221174A1 (fr) * 2016-06-22 2017-12-28 Novartis Ag Méthodes de traitement du vitiligo à l'aide d'anticorps de l'interleukine-17 (il -17)
EP3487881B1 (fr) 2016-07-19 2024-08-21 Novartis AG Procédés de traitement du psoriasis de type en plaques d'apparition récente au moyen d'antagonistes de l'il-17
EP4031570A1 (fr) * 2019-09-20 2022-07-27 Novartis AG Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'interleukine-17 (il-17)
WO2023064850A1 (fr) * 2021-10-14 2023-04-20 Regeneron Pharmaceuticals, Inc. Traitement de l'uvéite au moyen d'inhibiteurs de l'aminopeptidase 1 du réticulum endoplasmique (erap1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (fr) * 2003-11-21 2005-06-09 Celltech R & D Limited Methode de traitement de la sclerose en plaques par inhibition de l'activite d'il-17
US7807155B2 (en) * 2004-08-05 2010-10-05 Novartis Ag IL-17 antagonistic antibodies
WO2013158821A2 (fr) * 2012-04-20 2013-10-24 Novartis Ag Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
WO2003073991A2 (fr) 2002-03-01 2003-09-12 Celltech R & D, Inc. Procedes destines a accroitre ou a reduire la densite osseuse
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
CA2637166A1 (fr) 2006-01-31 2007-10-18 Novartis Ag Anticorps antagonistes il-17
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
WO2008133722A2 (fr) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anticorps et diagnostics
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2114435A1 (fr) 2007-02-02 2009-11-11 Novartis AG Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
EP2131860B1 (fr) 2007-03-20 2013-12-18 Eli Lilly & Company Anticorps antisclérostine
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008338464A1 (en) 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
CA2737636A1 (fr) 2008-09-29 2010-04-01 Roche Glycart Ag Anticorps contre l'il 17 humaine et utilisations associees
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051422A1 (fr) * 2003-11-21 2005-06-09 Celltech R & D Limited Methode de traitement de la sclerose en plaques par inhibition de l'activite d'il-17
US7807155B2 (en) * 2004-08-05 2010-10-05 Novartis Ag IL-17 antagonistic antibodies
WO2013158821A2 (fr) * 2012-04-20 2013-10-24 Novartis Ag Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAETEN DOMINIQUE ET AL: "Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial", November 2013, LANCET (NORTH AMERICAN EDITION), VOL. 382, NR. 9906, PAGE(S) 1705-1713, ISSN: 0140-6736(print), XP002726555 *
LEONARDI CRAIG ET AL: "Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis", March 2012, NEW ENGLAND JOURNAL OF MEDICINE, VOL. 366, NR. 13, PAGE(S) 1190-1199, ISSN: 0028-4793(print), XP002726553 *
PAPP KIM A ET AL: "Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis", March 2012, NEW ENGLAND JOURNAL OF MEDICINE, VOL. 366, NR. 13, PAGE(S) 1181-1189, ISSN: 0028-4793(print), XP002726554 *

Also Published As

Publication number Publication date
WO2014155278A2 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
MX2014006158A (es) Metodos para el tratamiento de artritis psoriasica (psa) utilizando antagonistas de il-17 y alelos con respuesta o sin respuesta a la psa.
WO2013158821A3 (fr) Procédés de traitement de la spondylarthrite ankylosante en utilisant des antagonistes de il-17
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
MX392435B (es) Anticuerpos estables y solubles que inhiben el vegf.
EP4311558A3 (fr) Anticorps qui se lient à il-23
EP4241852A3 (fr) Anticorps se liant à fcrn pour le traitement de maladies auto-immunes
EA201591478A1 (ru) Биспецифические антитела против фно и ил-17
PH12022551580A1 (en) Anti-ctla-4 antibody and use thereof
UA115657C2 (uk) Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
UA114108C2 (uk) Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
TR201909531T4 (tr) Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
PH12012501617A1 (en) Antagonist anti-il-7 receptor antibodies and methods
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
EA201690256A1 (ru) Система и способ планирования площадки для транспортных средств
MX2016001601A (es) Separacion de anticuerpos biespecificos y subproductos de produccion de anticuerpos biespecificos utilizando cromatografia de hidroxiapatita.
HK1213051A1 (zh) 用於预测和监测粘膜愈合的方法
WO2016170187A3 (fr) Biomarqueurs de détermination de la réponse clinique à une thérapie cellulaire
SG10201903424RA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
GB201210328D0 (en) Biomarker
TH169590A (th) แอนติบอดีที่ยึดเกาะ il-23
Berra et al. Use of a Monoclonal antibody (5H5) recognizing FH but not FHL-1 and FHRs to study FH in aHUS patients
UA110226C2 (en) Antibodies to cd38

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14718170

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14718170

Country of ref document: EP

Kind code of ref document: A2